Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restricted anti-PD-(L)1 therapy.

Methods

All patients with advanced cancers treated with anti-PD-(L)1 therapy outside clinical trials at Oulu University Hospital 2014-19 were retrospectively identified from pharmacy records. Clinical variables, treatment history and survival were collected.

Results

106 patients with median age of 66 years with lung cancer (n = 45, 42.5%), melanoma (n = 30, 28.3%), renal and bladder cancers (GU cancers) (n = 26, 24.5%), head and neck (H&N) cancer (n

SUBMITTER: Tikkanen A 

PROVIDER: S-EPMC7324422 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature